FAM174B and bladder transitional cell carcinoma: The study demonstrates that FAM174B promotes an immune-excluded tumor phenotype in BLCA while simultaneously predicting ICIs efficacy and molecular classification, providing clinicians with valuable information for therapeutic decision-making.